Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis

Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis

New HIV-1 infection rates far outpace the targets set by global health organizations, despite important progress in curbing the progression of the epidemic. Long-acting (LA) formulations delivering antiretroviral (ARV) agents for HIV-1 pre-exposure prophylaxis (PrEP) hold significant promise, potent...

Full description

Bibliographic Details
Main Authors: Manjula Gunawardana, Mariana Remedios-Chan, Debbie Sanchez, Simon Webster, Patricia Galvan, Rob Fanter, Amalia E. Castonguay, Paul Webster, John A. Moss, Joseph Kuo, Philippe A. Gallay, Kathleen L. Vincent, Massoud Motamedi, Dana Weinberger, Mark A. Marzinke, Craig W. Hendrix, Marc M. Baum
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Pharmacology
Subjects:
pre-exposure prophylaxis
long-acting
sustained release
tenofovir alafenamide
subdermal implant
HIV prevention
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2020.569373/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2020.569373/full

Similar Items